Peptide Half-Life Chart: Complete Reference Guide for Researchers (2026)

What Is a Peptide Half-Life Chart?

A peptide half-life chart is a reference tool used by laboratory researchers to quickly compare how long different peptides remain biologically active in plasma or buffer systems. Half-life, usually abbreviated as t½, is defined as the time required for the concentration of a substance to decline by 50% from its initial value. In peptide research, it is one of the single most useful numbers to know, because it directly influences dosing frequency in animal models, experimental timing, and the interpretation of pharmacodynamic results.

Peptide half-lives vary enormously. Small, unmodified peptides such as Sermorelin, Tesamorelin, and DSIP are cleaved by serum proteases within minutes, while lipidated or albumin-binding analogs such as Semaglutide, Tirzepatide, and Retatrutide remain detectable for days. This peptide half-life chart compiles the most commonly referenced half-life, storage, and handling values for twenty of the most widely studied research peptides as of 2026.

Complete Peptide Half-Life Chart

The table below summarizes plasma half-life, lyophilized storage temperature, reconstituted stability at 2–8 °C, and typical research dose ranges reported in the peer-reviewed literature and in pharmacokinetic modeling studies. Values are approximate and may vary depending on route of administration, formulation, species, and assay methodology. Researchers working with this peptide half-life chart should treat all entries as general guidelines rather than absolute constants.

All values are literature-reported approximations for research reference. Actual stability and pharmacokinetics depend on formulation, purity, diluent, and storage conditions.

How to Interpret Peptide Half-Life Chart Values

When reviewing a peptide half-life chart, it is important to remember that half-life is a statistical descriptor, not a hard cutoff. After one half-life, 50% of the peptide remains; after four to five half-lives, less than 5% remains, which is usually the point at which pharmacological effects are considered negligible. Researchers modeling repeat-dose experiments generally aim to reach steady-state concentrations after four to five half-lives of continuous administration.

Peptides with very short half-lives, such as Sermorelin and Tesamorelin, produce sharp, pulsatile signals that mimic physiological release patterns, which is often desirable when studying hypothalamic feedback loops. Peptides with long half-lives, such as Semaglutide and Retatrutide, produce smooth, sustained exposure that is favored for weekly-dosing pharmacokinetic and metabolic studies. Understanding how to read a peptide half-life chart correctly enables researchers to design more reproducible experiments.

For further reading on peptide pharmacokinetics, researchers may consult the PubMed database for peer-reviewed studies on peptide half-life and plasma clearance, the FDA Drugs database for approved peptide therapeutics and their pharmacokinetic profiles, and the NIH review on peptide stability for a comprehensive overview of factors that influence peptide degradation in biological systems.

How Half-Life Affects Dosing Frequency in Research Protocols

One of the most practical applications of a peptide half-life chart is calculating appropriate dosing intervals for in-vivo research models. In pharmacokinetic theory, a compound reaches approximately 97% of its steady-state plasma concentration after five consecutive half-life periods. This means that a peptide with a 2-hour half-life administered three times daily will reach steady-state within approximately 10 hours, while a peptide with a 7-day half-life like Semaglutide requires roughly 35 days to reach steady state with weekly dosing.

For short-acting peptides such as Sermorelin (t½ ~11–20 min), Tesamorelin (t½ ~26 min), and AOD-9604 (t½ ~30 min), pulsatile administration once or twice daily is the predominant research approach. Published data from growth hormone axis studies demonstrates that this pulsatile delivery pattern more accurately mimics endogenous GHRH secretion rhythms compared to continuous infusion models. Researchers frequently cross-reference a peptide half-life chart when selecting between modified and unmodified GHRH analogs precisely because this timing difference significantly affects experimental outcomes in hypothalamic-pituitary axis studies.

Long-acting analogs benefit from their extended half-lives in a different way. For GLP-1 receptor agonist studies, the once-weekly dosing enabled by Semaglutide, Tirzepatide, and Retatrutide allows for more consistent plasma levels throughout multi-week metabolic research protocols. A pharmacokinetic analysis of Retatrutide published in the Journal of Clinical Pharmacology reported a mean terminal half-life of approximately 6 days with a coefficient of variation below 30%, supporting reliable weekly dosing in primate models. Consulting a peptide half-life chart before initiating these protocols prevents the common error of applying short-acting dosing schedules to long-acting compounds. For more detail, see our Retatrutide dosage guide and our comprehensive peptide half-life chart reference.

Factors That Influence Peptide Half-Life

A printed or digital peptide half-life chart captures approximate values under standardized conditions, but several variables in the actual research environment can significantly shift observed half-life from the published reference. Understanding these factors helps researchers correctly interpret divergent pharmacokinetic observations and adjust experimental designs accordingly.

Molecular modifications are the primary driver of half-life engineering in modern peptide research. Native, unmodified peptides are typically cleaved rapidly by serum dipeptidyl peptidase-4 (DPP-4), neutral endopeptidase, and aminopeptidases. Fatty acid conjugation — as used in Semaglutide and Retatrutide — promotes reversible albumin binding that shields the peptide from enzymatic degradation and slows renal filtration, extending the half-life from minutes to days. The maleimide-DAC linker on CJC-1295 achieves the same result by a similar albumin-binding mechanism, extending half-life from 30 minutes to 6–8 days as reflected in the peptide half-life chart data above.

Route of administration also affects observed half-life. Intravenous delivery results in immediate full-concentration exposure and typically the shortest apparent half-life because peak plasma levels degrade the fastest. Subcutaneous injection produces a slower absorption phase that can extend the apparent terminal half-life. Intranasal delivery, used with Selank and Semax, bypasses first-pass enzymatic metabolism in some systems, which partially explains why researchers observe longer effective durations than the IV values listed in typical half-life reference data.

Species differences matter significantly. Rodent models metabolize many peptides 2–5 times faster than primates due to higher metabolic rate and plasma peptidase activity. When scaling protocols from rodent data to higher-order models, researchers should apply allometric correction factors rather than relying on raw values from a peptide half-life chart calibrated to one species. Published pharmacokinetic databases such as the allometric scaling review in Drug Metabolism Reviews provide correction factors for specific peptide classes.

Storage and formulation quality can dramatically reduce effective half-life before the experiment even begins. Peptide degradation during improper storage shortens the active fraction available at the time of administration. This is why the peptide half-life chart values for reconstituted stability are just as important as the plasma half-life values — both must be consulted together for accurate experimental planning. Review our detailed peptide storage guide and our guide on how to tell if a peptide has degraded to ensure sample integrity.

Storage Temperature and Handling

Virtually every research peptide should be stored lyophilized at -20 °C or colder in a sealed, desiccated environment. Some laboratories prefer -80 °C storage for highly hydrolytically sensitive sequences or when the peptide will be kept for more than a year. Repeated temperature cycling should be avoided, as moisture condensation on cold vials can initiate hydrolysis of amide and disulfide bonds. Proper storage directly preserves the peptide stability values listed in any accurate peptide half-life chart.

Light exposure also contributes to degradation, particularly for peptides containing tryptophan, tyrosine, methionine, or cysteine residues. Amber vials and opaque storage boxes are recommended. Peptides should always be brought to room temperature in a sealed container before opening to prevent water vapor from condensing on the powder, which would otherwise accelerate degradation of the reconstituted solution.

Reconstituted Stability Windows

The reconstituted stability window is the practical shelf life of a peptide after it has been dissolved in bacteriostatic water, sterile saline, or another suitable diluent. Once reconstituted, peptides begin to experience hydrolytic and enzymatic degradation, even when refrigerated. Most research peptides retain acceptable potency for two to six weeks at 2–8 °C, with stabilized long-acting analogs at the upper end of that range and unmodified peptides at the lower end. Any complete peptide half-life chart should list these reconstituted stability windows alongside plasma half-life values, as both inform proper research protocol design.

Bacteriostatic water containing 0.9% benzyl alcohol is generally preferred over plain sterile water because it suppresses microbial growth during multi-dose use. Researchers should always inspect reconstituted solutions for cloudiness, particulate formation, or color change before use, and discard any solution that appears degraded regardless of how recently it was prepared. For detailed reconstitution instructions, see our guide on how to reconstitute peptides and our article on bacteriostatic water.

Understanding Research Dose Ranges

The dose ranges shown in the peptide half-life chart reflect commonly reported laboratory research values and are not clinical recommendations. Dose ranges are often species- and model-dependent, with rodent studies using body-weight-normalized doses (mcg/kg or mg/kg) that may be substantially different from the fixed doses used in primate or pharmacokinetic models. When designing experiments, always consult primary literature for the specific model system in use and apply appropriate allometric scaling.

The relationship between half-life and dose range is not arbitrary. Peptides with very short half-lives typically require higher daily doses administered more frequently to maintain the target plasma concentration. Peptides with long half-lives deliver sustained exposure at lower total weekly doses. For context, the peptide half-life chart data shows that Semaglutide at 0.25–2.4 mg weekly achieves comparable research endpoints to Sermorelin at 100–500 mcg daily, a difference directly attributable to their 400-fold difference in half-life. To calculate specific dose volumes for your research, use our peptide dosage calculator guide.

Categories of Research Peptides

The peptides in this chart fall into several broad functional categories. Growth hormone secretagogues and GHRH analogs include Sermorelin, Tesamorelin, Ipamorelin, and CJC-1295. Incretin mimetics and metabolic peptides include Semaglutide, Tirzepatide, and Retatrutide. Tissue-repair and cytoprotective peptides include BPC-157, TB-500, and GHK-Cu. Immunomodulators include Thymosin Alpha-1 and KPV. Nootropic and neuropeptides include Selank, Semax, and DSIP. Melanocortin agonists include PT-141 and Melanotan II, while mitochondrial and longevity peptides include MOTS-C and Epithalon. Each category has characteristic pharmacokinetic behavior that is reflected in the half-life column of the peptide half-life chart above. Researchers looking for detailed pharmacokinetic data on individual peptides may benefit from our guides on BPC-157 research, proper peptide storage, and how to reconstitute peptides for accurate experimental results.

Peptide Half-Life Chart Accuracy and Limitations

Every peptide half-life chart represents a synthesis of published pharmacokinetic literature, and it is important for researchers to understand the inherent limitations of any such compilation. Half-life values are derived from specific assay conditions — typically IV bolus administration in a single species with healthy plasma — and may not reflect the pharmacokinetics observed under different experimental circumstances.

Variation between published studies is common. For example, Sermorelin half-life values in the literature range from 11 minutes to 20 minutes depending on whether the assay used radioimmunological detection or HPLC-MS, and whether the species was rat, dog, or human. Similarly, GHK-Cu plasma half-life estimates vary considerably based on whether researchers measure the tripeptide itself or the copper-chelated form. The peptide half-life chart values above represent midpoint consensus estimates from multiple sources and should be treated as starting-point references rather than definitive figures.

Another limitation is that the peptide half-life chart lists plasma half-life, which is the pharmacokinetic measure most commonly reported in the literature. Biological or pharmacodynamic half-life — the duration of measurable biological effect — can differ substantially. Thymosin Alpha-1, for example, has a plasma half-life of approximately 2 hours but exerts immunomodulatory effects for considerably longer periods, likely because of downstream signaling cascades that persist well beyond peptide clearance. Researchers should consult both pharmacokinetic and pharmacodynamic data when interpreting results from any peptide half-life chart reference. For a broader introduction to peptide research parameters, see our complete guide to peptides and our peptide glossary.

Best Practices for Peptide Handling

Researchers working with peptides should observe a few universal best practices. Always use clean, sterile technique when reconstituting lyophilized powder, and add diluent gently down the side of the vial rather than directly onto the peptide cake to minimize foaming and denaturation. Do not shake vials vigorously; gently swirl until fully dissolved. Label every reconstituted vial with the date, concentration, and diluent used. Keep a peptide log that records lot numbers, reconstitution dates, and stability observations so that results can be reproduced and anomalies traced back to a specific batch.

When using a peptide half-life chart to plan multi-day experiments, account for the reconstituted stability window as well as the plasma half-life. A peptide with a long plasma half-life but short reconstituted stability (two weeks or less) will require fresh preparation more frequently than the dosing interval suggests. Cross-reference both columns in the peptide half-life chart before scheduling preparation and dosing timelines. For additional guidance on research protocols, our peptide stacking guide provides context on combining multiple peptides with different half-lives in the same research protocol.

Finally, remember that the most reliable half-life and stability data are always those published in peer-reviewed pharmacokinetic studies for the specific peptide, formulation, and species of interest. This peptide half-life chart is a convenient starting point and a practical reference, not a substitute for primary literature review.